La REATA Pharmaceiticals annuncia l’approvazione del farmaco SKYCLARYS (omavaloxolone) indicato per pazienti con Atassia di Friedreich.

Posted on by

https://www.reatapharma.com/investors/news/news-details/2023/Reata-Pharmaceuticals-Announces-FDA-Approval-of-SKYCLARYS-Omavaloxolone-the-First-and-Only-Drug-Indicated-for-Patients-with-Friedreichs-Ataxia/default.aspx

 

FDA SKYCLARYS

Category: Comunicati stampa, Novita', Pubblicazioni scientifiche